August 12, 2021 7:39am
After last night’s close of a weak aftermarket, yet another Thursday’s indication?
The Biostage (BSTG) Chronicles: More questions emerge about the role of executive in “characterizing” financials pre the upcoming Q2 earnings’ release? <read more>
Earnings: BioLife Solutions (BLFS), Bellicum Pharmaceuticals (BLCM) Chinook Therapeutics (KDNY), Homology Medicine (FIXX)
Pre-open indications: 3 BUYs; 2 SELLs: 2 SELLs into Strength; 1 Maintain SELL
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
There is no breadline for fact and numbers-based share pricing intelligence!
Dow futures are UP +0.14% (+50 points), S&P futures are UP +0.07% (+3 point) and NASDAQ futures are UP +0.04% (+6 points)
U.S. stock futures were flat and weak in early premarket trade on Thursday,
European markets were mixed,
Asia-Pacific market declined with the continued spread of the delta variant.
Data Docket: weekly jobless claims data - claims are expected to total 375,000, down from 385,000 in the prior week.
Henry’omics:
There is no fizz in this market as it slurps along without a straw
The Labor Department reported that the consumer-price index rose 5.4% from a year earlier, for the month of July, and 0.5% from the previous month.
Wednesday’s evening’s recap: “volatility sucks pond water. What has not changed, sentiment resides in the toilet.” … https://www.regmedinvestors.com/articles/12044
- The Nasdaq closed DOWN – 22.95 points (-0.16%);
- The IBB closed down -2.99% and XBI closed down -0.65%
- Sector volume INCREASED with 4 of the 13-upside having higher than the 3-month average volume with very LOW volume of 4 of 16-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.73. points or -4.35% at 16.06;
- Wednesday’s percentage (%) of the 13-upside were +0.10% (SGMO) to +5.40% (EDIT) while the 16-downside -0.66% (MESO) to -7.76% (CLLS);
Q3/21:
- August: 4 positive and 4 negative closes
- July: 6 positives, 1 holiday and 15 negative closes
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
- BioLife Solutions (BLFS) – today;
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped/promoted”?
Biostage (BSTG) closed flat again on Wednesday with 50 shares traded following Tuesday with 4 shares traded, Monday’s down -$0.05 with 1060 shares traded, Friday’s +$0.05 on Friday with 709 shares traded and last Thursday with 5 shares traded.
Question#1: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?
Question#2: On July 9th an 8-K was issued saying “Wei & Wei and Co” was engaged. Are they registered in Massachusetts, not according to their website after RSM US LLP “walked” – i.e., “ceased their engagement”? So, when, is their quarterly earnings being released?
Question#3: Does VP of Business development and Operations, Shunfu Hu remember he left a message on a cell phone telling consultant he won’t be paid for work completed. Funny how many of other consultants’ billings have been “conveniently lost”; doesn’t that also involved “mis-characterizing” the financials for a year and a half?
Question#4: WHAT is the status of the $1,000,000 “gift” to Connecticut Childrens (hospital) where the CEO, James Schmerling of this hospital is a board of director member and $429 ,500.00 is still OWED (that is NOT listed as a payable in financials by BSTG, that is all but broke?
Question#5: BSTG has already admitted, with the inclusion of a disclosure (from reading) in a past 10-K, “identified a material weakness in our internal control over financial reporting. Our ability to remediate this, our discovery of additional weaknesses, and our ability to achieve and maintain effective control over financial reporting, could adversely affect our results of operations, our stock price and investor confidence in our company.”
Question#6: Does it also put MORE fiduciary and transparency responsibility on board and audit committee members, Herman Sanchez of Trinity Consulting and James Schmerling of Connecticut Children’s hospital be more than concerned with their potential liabilities and loss?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
Pre-open Indications: the dice get rolled in this frenetic market and resulting sector bumps and dumps
SELL into Strength:
Intellia Therapeutics (NTLA) closed up +$3.84 with a positive +$0.34 or +0.21% aftermarket indication
bluebird bio (BLUE) with a positive +$0.09 or +0.47% pre-market indication,
SELL:
Applied Genetic Technologies (AGTC) closed down -$0.10 and has a negative -$0.05 or -1.37% pre-market indication,
Mesoblast (MESO) closed down last session and has a negative -$0.22 or -2.95% pre-market indication,
BUY:
CRISPR Therapeutics (CRSP) closed down -$1.47 with a positive +$0.45 aftermarket indication,
Global Blood Therapeutics (GBT) with a positive +$1.00 or +3.33% aftermarket indication
Sage Therapeutics (SAGE) with a positive +$0.81% or +1.88% pre-market indication
The BOTTOM LINE: The recent bout of pricing inconsistency in the cell and gene therapy sector could be chalked up to LACK of any … impression of any kind in my 35 covered companies in this Q2 earnings season.
I was skittish over Friday and NERVOUS as Monday while Tuesday and Wednesday didn’t seem to be taking shape and again Thursday will be dependent on macro-economic numbers – re direction.
The cell and gene therapy sector has experience dramatic upside move and downside putting a real edge on share pricing as earnings continued to guide sector sentiment … following last week’s twenty-one (21) releases to date – hey, one (1) today.
Q2 earnings potential LPS (loss-per-share): coming “attractions”
- BioLife Solutions (BLFS) – 8/12
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC), Bellicum Pharmaceuticals (BLCM), Biostage (BSTG), Homology medicine (FIXX), Mesoblast (MESO), Pluristem (PSTI) and Solid Biosciences (SLDB)
Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.
Risk is no doubt increasing as we head into the troublesome August and September months
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
